MP85-13: Erectile function in 478 hypogonadal men w ... ut testosterone therapy for up to 10 years (APL - 2018)

Erectile function in 478 hypogonadal men with moderate to severe ED with and without testosterone therapy for up to 10 years

View Poster


Long-term data for treatment of erectile dysfunction (ED) are scarce. We investigated effects of testosterone therapy (TTh) in a registry study in a urological office setting in comparison to an untreated hypogonadal control group.


478 men with testosterone ≤350 ng/dL and hypogonadal symptoms had moderate to severe ED according to IIEF-EF (5+1, maximum score: 30). 246 received testosterone undecanoate injections (TU) 1000 mg/12 weeks following an initial 6-week interval (T-group). 232 men opted against TTh and served as controls (CTRL). 10-year data are presented. Changes over time between groups were compared by a mixed effects model for repeated measures with a random effect for intercept and fixed effects for time, group and their interaction, and adjusted for age, weight, waist circumference, blood pressure, fasting glucose, lipids and quality of life to account for baseline differences between groups.


Total group: mean age was 61±7 years (T-group: 58±8, CTRL: 64±5). 34% of men in the T-group and 44% in CTRL had type 2 diabetes at baseline (p


TTh in hypogonadal men improves erectile function over a long period of time. It deteriorates in untreated hypogonadal men. These results may in part be mediated by changes in body weight.

Funding: Statistical analyses and data entry were partially funded by Bayer AG, Berlin, Germany.